

Gavin J Churchyard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4439853/publications.pdf>

Version: 2024-02-01

193
papers

12,603
citations

31976

53
h-index

28297

105
g-index

198
all docs

198
docs citations

198
times ranked

12518
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophils Contribute to Severity of Tuberculosis Pathology and Recovery From Lung Damage Pre- and Posttreatment. <i>Clinical Infectious Diseases</i> , 2022, 74, 1757-1766.	5.8	11
2	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 507-518.	9.1	28
3	Plasma host protein biomarkers correlating with increasing <i>Mycobacterium tuberculosis</i> infection activity prior to tuberculosis diagnosis in people living with HIV. <i>EBioMedicine</i> , 2022, 75, 103787.	6.1	12
4	Sub-Lineage Specific Phenolic Glycolipid Patterns in the <i>Mycobacterium tuberculosis</i> Complex Lineage 1. <i>Frontiers in Microbiology</i> , 2022, 13, 832054.	3.5	3
5	The effect of host factors on discriminatory performance of a transcriptomic signature of tuberculosis risk. <i>EBioMedicine</i> , 2022, 77, 103886.	6.1	2
6	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. <i>Communications Medicine</i> , 2022, 2, .	4.2	15
7	<i>Mycobacterium tuberculosis</i> infection, immune activation, and risk of HIV acquisition. <i>PLoS ONE</i> , 2022, 17, e0267729.	2.5	2
8	Health-related quality of life and psychological distress among adults in Tanzania: a cross-sectional study. <i>Archives of Public Health</i> , 2022, 80, .	2.4	1
9	Monocyte Transcriptional Responses to <i>Mycobacterium tuberculosis</i> Associate with Resistance to Tuberculin Skin Test and Interferon Gamma Release Assay Conversion. <i>MSphere</i> , 2022, 7, .	2.9	8
10	Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa. <i>Global Health Action</i> , 2021, 14, 1865625.	1.9	6
11	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. <i>European Respiratory Journal</i> , 2021, 58, 2003492.	6.7	27
12	Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 354-365.	9.1	84
13	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. <i>Npj Vaccines</i> , 2021, 6, 56.	6.0	7
14	Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis. <i>PLoS ONE</i> , 2021, 16, e0251547.	2.5	4
15	Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. <i>The Lancet Global Health</i> , 2021, 9, e841-e853.	6.3	34
16	Seroprevalence of <i>Aspergillus</i> -Specific IgG Antibody among Mozambican Tuberculosis Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 595.	3.5	7
17	Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 897-908.	10.7	64
18	Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis. <i>PLoS Medicine</i> , 2021, 18, e1003738.	8.4	18

#	ARTICLE	IF	CITATIONS
19	Causes and Outcomes of Admission and Investigation of Tuberculosis in Adults with Advanced HIV in South African Hospitals: Data from the TB Fast Track Trial. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	3
20	Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial. Lancet HIV,the, 2020, 7, e27-e37.	4.7	32
21	Monitoring Anti-tuberculosis Treatment Response Using Analysis of Whole Blood Mycobacterium tuberculosis Specific T Cell Activation and Functional Markers. Frontiers in Immunology, 2020, 11, 572620.	4.8	10
22	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Scientific Reports, 2020, 10, 13031.	3.3	10
23	Costâ€effectiveness of a 12 countryâ€™intervention to scale up short course TB preventive therapy among people living with HIV. Journal of the International AIDS Society, 2020, 23, e25629.	3.0	4
24	Predictors of silicosis and variation in prevalence across mines among employed gold miners in South Africa. BMC Public Health, 2020, 20, 829.	2.9	18
25	Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. MSphere, 2020, 5, .	2.9	3
26	Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV,the, 2020, 7, e401-e409.	4.7	41
27	Title is missing!. , 2020, 15, e0243707.		0
28	Title is missing!. , 2020, 15, e0243707.		0
29	Title is missing!. , 2020, 15, e0243707.		0
30	Title is missing!. , 2020, 15, e0243707.		0
31	Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis. Journal of Infectious Diseases, 2019, 220, S99-S107.	4.0	19
32	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. Lancet Respiratory Medicine,the, 2019, 7, 820-826.	10.7	92
33	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. The Lancet Global Health, 2019, 7, e191-e199.	6.3	53
34	Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB. PLoS Medicine, 2019, 16, e1002787.	8.4	31
35	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
36	A Short Regimen for Rifampin-Resistant Tuberculosis. New England Journal of Medicine, 2019, 380, 1279-1280.	27.0	8

#	ARTICLE	IF	CITATIONS
37	Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa. <i>PLoS ONE</i> , 2019, 14, e0209320.	2.5	9
38	Patient costs incurred by people living with HIV/AIDS prior to ART initiation in primary healthcare facilities in Gauteng, South Africa. <i>PLoS ONE</i> , 2019, 14, e0210622.	2.5	9
39	Heat Inactivation Renders Sputum Safe and Preserves <i>Mycobacterium tuberculosis</i> RNA for Downstream Molecular Tests. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	15
40	Protein binding of rifampicin is not saturated when using high-dose rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 986-990.	3.0	13
41	TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB – a study protocol. <i>BMC Pulmonary Medicine</i> , 2019, 19, 4.	2.0	45
42	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, 34-41.	5.8	80
43	Small contribution of gold mines to the ongoing tuberculosis epidemic in South Africa: a modeling-based study. <i>BMC Medicine</i> , 2018, 16, 52.	5.5	11
44	Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. <i>Clinical Infectious Diseases</i> , 2018, 67, 1072-1078.	5.8	43
45	Pan-tuberculosis regimens: an argument for. <i>Lancet Respiratory Medicine</i> , 2018, 6, 239-240.	10.7	16
46	Performance of verbal autopsy methods in estimating HIV-associated mortality among adults in South Africa. <i>BMJ Global Health</i> , 2018, 3, e000833.	4.7	7
47	A stratified approach to tuberculosis treatment. <i>Nature Medicine</i> , 2018, 24, 1639-1641.	30.7	8
48	Using mHealth to improve tuberculosis case identification and treatment initiation in South Africa: Results from a pilot study. <i>PLoS ONE</i> , 2018, 13, e0199687.	2.5	22
49	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. <i>European Respiratory Journal</i> , 2018, 52, 1800946.	6.7	27
50	Empiric tuberculosis treatment in South African primary health care facilities - for whom, where, when and why: Implications for the development of tuberculosis diagnostic tests. <i>PLoS ONE</i> , 2018, 13, e0191608.	2.5	12
51	Linkage to care among adults being investigated for tuberculosis in South Africa: pilot study of a case manager intervention. <i>BMJ Open</i> , 2018, 8, e021111.	1.9	4
52	Immunological mechanisms of human resistance to persistent <i>Mycobacterium tuberculosis</i> infection. <i>Nature Reviews Immunology</i> , 2018, 18, 575-589.	22.7	241
53	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. <i>Tuberculosis</i> , 2018, 109, 61-68.	1.9	28
54	Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa. <i>PLoS ONE</i> , 2018, 13, e0192089.	2.5	5

#	ARTICLE	IF	CITATIONS
55	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018, 14, e1006888.	4.7	26
56	Target regimen profiles for treatment of tuberculosis: a WHO document. <i>European Respiratory Journal</i> , 2017, 49, 1602352.	6.7	25
57	Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation. <i>The Lancet Global Health</i> , 2017, 5, e710-e719.	6.3	53
58	Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation After HIV Diagnosis: A Randomized Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 540-547.	2.1	17
59	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2017, 5, 291-360.	10.7	459
60	The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa. <i>Health Policy and Planning</i> , 2017, 32, iv48-iv56.	2.7	35
61	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. <i>Lancet Infectious Diseases</i> , 2017, 17, 39-49.	9.1	294
62	Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?. <i>Journal of Infectious Diseases</i> , 2017, 216, S662-S668.	4.0	17
63	What We Know About Tuberculosis Transmission: An Overview. <i>Journal of Infectious Diseases</i> , 2017, 216, S629-S635.	4.0	193
64	Tuberculosis Infectiousness and Host Susceptibility. <i>Journal of Infectious Diseases</i> , 2017, 216, S636-S643.	4.0	65
65	Impact of Targeted Tuberculosis Vaccination Among a Mining Population in South Africa: A Model-Based Study. <i>American Journal of Epidemiology</i> , 2017, 186, 1362-1369.	3.4	13
66	Measuring mortality due to HIV-associated tuberculosis among adults in South Africa: Comparing verbal autopsy, minimally-invasive autopsy, and research data. <i>PLoS ONE</i> , 2017, 12, e0174097.	2.5	24
67	Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. <i>PLoS Medicine</i> , 2017, 14, e1002202.	8.4	20
68	A clinical scoring system to prioritise investigation for tuberculosis among adults attending HIV clinics in South Africa. <i>PLoS ONE</i> , 2017, 12, e0181519.	2.5	28
69	Verbal autopsy-assigned causes of death among adults being investigated for TB in South Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2016, 110, 510-516.	1.8	10
70	The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. <i>BMC Infectious Diseases</i> , 2016, 16, 266.	2.9	8
71	Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV Enrolled in Out-Patient Care in South Africa. <i>PLoS ONE</i> , 2016, 11, e0166158.	2.5	42
72	Clinic-level factors influencing patient outcomes on antiretroviral therapy in primary health clinics in South Africa. <i>Aids</i> , 2016, 30, 1099-1109.	2.2	9

#	ARTICLE	IF	CITATIONS
73	Detection and Quantification of Differentially Culturable Tubercle Bacteria in Sputum from Patients with Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1532-1540.	5.6	105
74	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. <i>The Lancet Global Health</i> , 2016, 4, e806-e815.	6.3	138
75	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. <i>The Lancet Global Health</i> , 2016, 4, e816-e826.	6.3	69
76	Using Top-down and Bottom-up Costing Approaches in LMICs: The Case for Using Both to Assess the Incremental Costs of New Technologies at Scale. <i>Health Economics (United Kingdom)</i> , 2016, 25, 53-66.	1.7	74
77	Outcomes of on-site antiretroviral therapy provision in a South African correctional facility. <i>International Journal of STD and AIDS</i> , 2016, 27, 1153-1161.	1.1	14
78	Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e34-e46.	9.1	223
79	The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. <i>BMC Medicine</i> , 2016, 14, 45.	5.5	18
80	Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1187-1197.	13.7	211
81	Household HIV Testing Uptake among Contacts of TB Patients in South Africa. <i>PLoS ONE</i> , 2016, 11, e0155688.	2.5	14
82	Diagnostic Accuracy of Lateral Flow Urine LAM Assay for TB Screening of Adults with Advanced Immunosuppression Attending Routine HIV Care in South Africa. <i>PLoS ONE</i> , 2016, 11, e0156866.	2.5	17
83	Cost-Effectiveness of Automated Digital Microscopy for Diagnosis of Active Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0157554.	2.5	9
84	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , 2016, 11, e0161753.	2.5	16
85	Brief Report. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 104-108.	2.1	6
86	Regarding the effect of cured tuberculosis disease on longevity. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 367-367.	1.2	0
87	Trends in silicosis prevalence and the healthy worker effect among gold miners in South Africa: a prevalence study with follow up of employment status. <i>BMC Public Health</i> , 2015, 15, 1258.	2.9	33
88	Clinical Relevance of Nontuberculous Mycobacteria Isolated from Sputum in a Gold Mining Workforce in South Africa: An Observational, Clinical Study. <i>BioMed Research International</i> , 2015, 1-10.	1.9	14
89	Tuberculosis Prevention in South Africa. <i>PLoS ONE</i> , 2015, 10, e0122514.	2.5	17
90	The Diagnostic Accuracy of Urine Lipoarabinomannan Test for Tuberculosis Screening in a South African Correctional Facility. <i>PLoS ONE</i> , 2015, 10, e0127956.	2.5	10

#	ARTICLE	IF	CITATIONS
91	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	2.5	23
92	Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4 ⁺ T Cells. <i>Vaccine Journal</i> , 2015, 22, 688-696.	3.1	10
93	Molecular Epidemiology of <i>Mycobacterium tuberculosis</i> among South African Gold Miners. <i>Annals of the American Thoracic Society</i> , 2015, 12, 12-20.	3.2	14
94	The economic burden of TB diagnosis and treatment in South Africa. <i>Social Science and Medicine</i> , 2015, 130, 42-50.	3.8	122
95	The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4 ⁺ T cell counts ≥ 350 cells/mm ³ . <i>Vaccine</i> , 2015, 33, 1890-1896.	3.8	35
96	The relationship between <i>Mycobacterium tuberculosis</i> MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 448-455.	3.0	58
97	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
98	Implementing a Large-Scale Systematic Tuberculosis Screening Program in Correctional Facilities in South Africa. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu121.	0.9	13
99	Molecular characterisation of clinical and environmental isolates of <i>Mycobacterium kansasii</i> isolates from South African gold mines. <i>Journal of Water and Health</i> , 2015, 13, 190-202.	2.6	12
100	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. <i>The Lancet Global Health</i> , 2015, 3, e450-e457.	6.3	179
101	Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 511-512.	46.4	110
102	Tuberculosis active case finding: uptake and diagnostic yield among minibus drivers in urban South Africa. <i>BMC Public Health</i> , 2015, 15, 242.	2.9	4
103	Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial. <i>Trials</i> , 2015, 16, 125.	1.6	13
104	Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1443-1449.	5.6	25
105	Tuberculosis Control in South African Gold Mines: Mathematical Modeling of a Trial of Community-Wide Isoniazid Preventive Therapy. <i>American Journal of Epidemiology</i> , 2015, 181, 619-632.	3.4	38
106	The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001869.	8.4	15
107	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , 2015, 10, e0137666.	2.5	30
108	Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial. <i>PLoS ONE</i> , 2015, 10, e0138149.	2.5	41

#	ARTICLE	IF	CITATIONS
109	Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection. PLoS ONE, 2014, 9, e89612.	2.5	101
110	Tuberculosis preventive therapy: An underutilised strategy to reduce individual risk of TB and contribute to TB control. South African Medical Journal, 2014, 104, 339.	0.6	18
111	The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants. International Journal of STD and AIDS, 2014, 25, 332-340.	1.1	5
112	A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control. New England Journal of Medicine, 2014, 370, 301-310.	27.0	194
113	Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. Journal of Infectious Diseases, 2014, 209, 711-720.	4.0	47
114	A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control. New England Journal of Medicine, 2014, 370, 1661-1663.	27.0	13
115	Durable <scp>HIV RNA</scp> resuppression after virologic failure while remaining on a first-line regimen: a cohort study. Tropical Medicine and International Health, 2014, 19, 236-239.	2.3	10
116	Tuberculosis Vaccines and Prevention of Infection. Microbiology and Molecular Biology Reviews, 2014, 78, 650-671.	6.6	133
117	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infectious Diseases, The, 2014, 14, 388-396.	9.1	108
118	Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet, The, 2014, 383, 424-435.	13.7	379
119	High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis. New England Journal of Medicine, 2014, 371, 1599-1608.	27.0	383
120	High Tuberculosis Prevalence in a South African Prison: The Need for Routine Tuberculosis Screening. PLoS ONE, 2014, 9, e87262.	2.5	61
121	Four Models of HIV Counseling and Testing: Utilization and Test Results in South Africa. PLoS ONE, 2014, 9, e102267.	2.5	46
122	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses. PLoS ONE, 2014, 9, e103446.	2.5	9
123	Incidence of HIV-Associated Tuberculosis among Individuals Taking Combination Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e111209.	2.5	31
124	Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa. PLoS ONE, 2014, 9, e112303.	2.5	5
125	Safety and Immunogenicity of H1/IC31A®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm ³ : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS ONE, 2014, 9, e114602.	2.5	52
126	Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infectious Diseases, 2013, 13, 352.	2.9	47

#	ARTICLE	IF	CITATIONS
127	The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. <i>European Respiratory Journal</i> , 2013, 42, 1604-1613.	6.7	683
128	Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward?. <i>International Journal of Health Services</i> , 2013, 43, 651-664.	2.5	18
129	Mortality Associated With Delays Between Clinic Entry and ART Initiation in Resource-Limited Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 63, 105-111.	2.1	30
130	Resistance to Tenofovir-Based Regimens during Treatment Failure of Subtype C HIV-1 in South Africa. <i>Antiviral Therapy</i> , 2013, 18, 915-920.	1.0	19
131	Tuberculosis: The global killer. <i>South African Journal of Science</i> , 2013, 109, 2.	0.7	2
132	Improved services to enrollees into an HIV rural care and treatment center in Tanzania. <i>Pan African Medical Journal</i> , 2013, 16, 34.	0.8	0
133	Comparison of Tenofovir, Zidovudine, or Stavudine as Part of First-Line Antiretroviral Therapy in a Resource-Limited-Setting: A Cohort Study. <i>PLoS ONE</i> , 2013, 8, e64459.	2.5	59
134	Eligibility for Isoniazid Preventive Therapy in South African Gold Mines. <i>PLoS ONE</i> , 2013, 8, e81376.	2.5	6
135	A novel HIV treatment model using private practitioners in South Africa. <i>Sexually Transmitted Infections</i> , 2012, 88, 136-140.	1.9	15
136	Outcomes Following Virological Failure and Predictors of Switching to Second-line Antiretroviral Therapy in a South African Treatment Program. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 370-380.	2.1	43
137	Undiagnosed Tuberculosis Among HIV Clinic Attendees. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, e22-e28.	2.1	39
138	Genotype MTBDRplus for Direct Detection of Mycobacterium tuberculosis and Drug Resistance in Strains from Gold Miners in South Africa. <i>Journal of Clinical Microbiology</i> , 2012, 50, 1189-1194.	3.9	35
139	Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women. <i>PLoS ONE</i> , 2012, 7, e31387.	2.5	8
140	Second-Line Antiretroviral Therapy in a Workplace and Community-Based Treatment Programme in South Africa: Determinants of Virological Outcome. <i>PLoS ONE</i> , 2012, 7, e36997.	2.5	29
141	“Proof-Of-Concept” Evaluation of an Automated Sputum Smear Microscopy System for Tuberculosis Diagnosis. <i>PLoS ONE</i> , 2012, 7, e50173.	2.5	35
142	Performance Characteristics of the Cepheid Xpert MTB/RIF Test in a Tuberculosis Prevalence Survey. <i>PLoS ONE</i> , 2012, 7, e43307.	2.5	51
143	Contrasting Reasons for Discontinuation of Antiretroviral Therapy in Workplace and Public-Sector HIV Programs in South Africa. <i>AIDS Patient Care and STDs</i> , 2011, 25, 53-59.	2.5	26
144	Thibela TB: Design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa. <i>Contemporary Clinical Trials</i> , 2011, 32, 382-392.	1.8	31

#	ARTICLE	IF	CITATIONS
145	Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases</i> , 2011, 11, 507-515.	9.1	330
146	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). <i>PLoS ONE</i> , 2011, 6, e21225.	2.5	131
147	What Is Thwarting Tuberculosis Prevention in High-Burden Settings?. <i>New England Journal of Medicine</i> , 2011, 365, 79-81.	27.0	17
148	Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial. <i>Thorax</i> , 2011, 66, 134-139.	5.6	22
149	Diagnosing Latent Tuberculosis in High-Risk Individuals: Rising to the Challenge in High-Burden Areas. <i>Journal of Infectious Diseases</i> , 2011, 204, S1168-S1178.	4.0	38
150	Changing Predictors of Mortality Over Time From cART Start. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 269-276.	2.1	37
151	Diagnostic Accuracy of a Urine Lipoarabinomannan Enzyme-Linked Immunosorbent Assay for Screening Ambulatory HIV-Infected Persons for Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 58, 219-223.	2.1	30
152	Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. <i>PLoS Medicine</i> , 2011, 8, e1000391.	8.4	328
153	Cytomegalovirus Viremia as a Risk Factor for Mortality Prior to Antiretroviral Therapy among HIV-Infected Gold Miners in South Africa. <i>PLoS ONE</i> , 2011, 6, e25571.	2.5	40
154	Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. <i>Aids</i> , 2010, 24, 1051-1055.	2.2	55
155	Isoniazid preventive therapy for HIV-infected people: evidence to support implementation. <i>Aids</i> , 2010, 24, S1-S3.	2.2	12
156	“Team up against TB”: promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy. <i>Aids</i> , 2010, 24, S37-S44.	2.2	13
157	Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. <i>Aids</i> , 2010, 24, 1709-1716.	2.2	31
158	Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. <i>Aids</i> , 2010, 24, S5-S13.	2.2	34
159	Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. <i>BMC Public Health</i> , 2010, 10, 430.	2.9	30
160	Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. <i>BMC Public Health</i> , 2010, 10, 433.	2.9	32
161	Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. <i>Bulletin of the World Health Organization</i> , 2010, 88, 13-21.	3.3	69
162	Recurrent Tuberculosis: Relapse, Reinfection, and HIV. <i>Journal of Infectious Diseases</i> , 2010, 201, 653-655.	4.0	52

#	ARTICLE	IF	CITATIONS
163	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. <i>Journal of Virology</i> , 2010, 84, 630-638.	3.4	57
164	Symptom and chest radiographic screening for infectious tuberculosis prior to starting isoniazid preventive therapy: yield and proportion missed at screening. <i>Aids</i> , 2010, 24, S19-S27.	2.2	22
165	Adverse events with isoniazid preventive therapy: experience from a large trial. <i>Aids</i> , 2010, 24, S29-S36.	2.2	42
166	Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. <i>Aids</i> , 2010, 24, S45-S48.	2.2	72
167	Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?. <i>Aids</i> , 2010, 24, S15-S18.	2.2	8
168	Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. <i>Lancet, The</i> , 2010, 375, 2179-2191.	13.7	114
169	Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. <i>Lancet, The</i> , 2010, 376, 1244-1253.	13.7	276
170	Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 489-498.	9.1	165
171	Opportunities afforded by new drugs for tuberculosis. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 368-369.	9.1	2
172	Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy in South Africa. <i>Clinical Infectious Diseases</i> , 2009, 49, 1928-1935.	5.8	107
173	HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa. <i>Aids</i> , 2009, 23, 1784-1786.	2.2	8
174	HIV Infection Does Not Affect Active Case Finding of Tuberculosis in South African Gold Miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 1271-1278.	5.6	48
175	Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former basotho gold miners. <i>American Journal of Industrial Medicine</i> , 2009, 52, 901-908.	2.1	41
176	The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2009, 360, 2397-2405.	27.0	763
177	HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. <i>Lancet, The</i> , 2009, 374, 921-933.	13.7	414
178	Achieving the health Millennium Development Goals for South Africa: challenges and priorities. <i>Lancet, The</i> , 2009, 374, 1023-1031.	13.7	214
179	Expanding HIV care in Africa: making men matter in Johannesburg. <i>Lancet, The</i> , 2009, 374, 1329.	13.7	14
180	Advances in Immunotherapy for Tuberculosis Treatment. <i>Clinics in Chest Medicine</i> , 2009, 30, 769-782.	2.1	54

#	ARTICLE	IF	CITATIONS
181	Epidemiology of HIV-associated tuberculosis. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 325-333.	3.8	145
182	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa: authors' reply. <i>Aids</i> , 2009, 23, 872-873.	2.2	0
183	Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study. <i>BMC Infectious Diseases</i> , 2008, 8, 93.	2.9	40
184	The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers. <i>American Journal of Industrial Medicine</i> , 2008, 51, 640-647.	2.1	64
185	"That is why I stopped the ART": Patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. <i>BMC Public Health</i> , 2008, 8, 63.	2.9	122
186	Hepatitis B Virus Infection and Response to Antiretroviral Therapy (ART) in a South African ART Program. <i>Clinical Infectious Diseases</i> , 2008, 47, 1479-1485.	5.8	119
187	Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. <i>Aids</i> , 2008, 22, 1971-1977.	2.2	195
188	Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease. <i>PLoS Medicine</i> , 2007, 4, e22.	8.4	106
189	Tuberculosis Preventive Therapy in the Era of HIV Infection: Overview and Research Priorities. <i>Journal of Infectious Diseases</i> , 2007, 196, S52-S62.	4.0	70
190	Human Immunodeficiency Virus and the Prevalence of Undiagnosed Tuberculosis in African Gold Miners. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 673-679.	5.6	154
191	Morbidity and Mortality in South African Gold Miners: Impact of Untreated Disease Due to Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2002, 34, 1251-1258.	5.8	169
192	HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. <i>Aids</i> , 2000, 14, 2759-2768.	2.2	153
193	Tuberculosis and HIV. , 0, , 457-478.		0